SMV + SOF With/Without RBV for IFN-II Patients With CHC

Inclusion Criteria: 1. Targeted at least 20% enrollment of patients with cirrhosis 2. Adults \>/= age 18 years. 3. Active infection with hepatitis C virus (HCV) genotype 1 4. Must have health insurance that covers therapy with SOF+RBV 5. Female patients of childbearing age must have a negative pregnancy test prior to initiating therapy, use at least two effective methods of contraception during treatment, and undergo monthly pregnancy tests. 6. Patients must be either IFN-ineligible due to psychiatric, autoimmune, neurological, or other causes that are confirmed appropriate by the PI; OR, 7. IFN-intolerant due to flu-like symptoms, psychiatric problems, cytopenia or other causes deemed appropriate by the PI. Exclusion Criteria: 1. Presence of HIV co-infection 2. Presence of hepatocellular carcinoma (HCC) 3. Prior organ transplantation 4. Any history of hepatic decompensation 5. Patients taking any of the following medications: * Anticonvulsants- Carbamazepine, Oxcarbazepine, Phenobarbital, or Phenytoin. * Anti-infectives-erythromycin, clarithromycin, or telithromycin. * Antifungals- systemic itraconazole, ketoconazole, posaconazole, fluconazole, or voriconazole. * Antimycobacterials- rifampin, rifabutin or rifapentine. * Corticosteroids- systemic dexamethasone. * Propulsives- Cisapride. * Herbals- Milk thistle or St. John's Wart. 6. Patients that have been exposed to direct acting anti-viral agents 7. Patients with severe renal impairment (estimated Glomerular Filtration Rate (eGFR) \<50 mL/min/1.73m2) or with end stage renal disease (ESRD). 8. Patients with platelet count \<50 x109/L, Hemoglobin \<10 g/dL, or Neutrophils \<0.5 x109/L. 9. Women who are pregnant. 10. Men whose partners are pregnant or plan on becoming pregnant.